Scisparc announces recruitment of first patient for its phase iia clinical trial in alzheimer's disease

Tel aviv, israel, jan. 6, 2022 /prnewswire/ -- scisparc ltd. (nasdaq: sprc) (the "company"), a clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the israeli medical center for alzheimer's has recruited the first patient to participate in the company's phase iia clinical trial that will evaluate the safety, tolerability and efficacy of sci-110 in patients with alzheimer's disease and agitation using the company's proprietary cannabinoid-based technology.
SPRC Ratings Summary
SPRC Quant Ranking